Novartis eyes oral ms drug as potential blockbuster

Access through your institution Buy or subscribe The newly approved drug provides “a compelling treatment option to needle-phobic patients,” says Joel Sendek of Lazard Capital Markets in New

York. Over time, it will take share away from other treatments, he says, “as patients discouraged with monthly infusions elect to switch, and physicians and patients gain comfort with the

safety and tolerability profile.” Gilenya—approved to reduce relapses and delay disability progression—is competing with Tysabri (natalizumab), which Cambridge, Massachusetts firm Biogen

Idec co-markets with Dublin-based Elan, as well as several formulations of interferon (IFN)-β1a, for a share of the $11 billion, and growing, MS market. There are 400,000 people in the US

with MS and over 2 million worldwide. The US go-ahead follows the drug's approval in Russia earlier in the month; it is still under consideration by European regulators. This is a

preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 12 print issues and online access $209.00 per

year only $17.42 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated

during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support AUTHOR INFORMATION AUTHORS AND AFFILIATIONS *

Cambridge, Massachusetts Mark Ratner Authors * Mark Ratner View author publications You can also search for this author inPubMed Google Scholar RIGHTS AND PERMISSIONS Reprints and

permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Ratner, M. Novartis eyes oral MS drug as potential blockbuster. _Nat Biotechnol_ 28, 1135–1136 (2010). https://doi.org/10.1038/nbt1110-1135

Download citation * Published: 05 November 2010 * Issue Date: November 2010 * DOI: https://doi.org/10.1038/nbt1110-1135 SHARE THIS ARTICLE Anyone you share the following link with will be

able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing

initiative